Ulcerative Colitis | Unmet Need | Moderate to Severe | US/EU | 2023

TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s Stelara) are the mainstays of treatment for UC. However, these agents have safety risks and efficacy limitations. Newer alternatives, such as JAK inhibitors (Pfizer’s Xeljanz and AbbVie’s Rinvoq), an IL-23 inhibitor (Eli Lilly’s Omvoh), and S1P-R modulators (BMS’s Zeposia and Pfizer’s Velsipity) have expanded the treatment options, but significant unmet need remains for patients whose UC is refractory to these therapies. Although several agents with novel mechanisms of action are poised to enter market over the next several years, their ability to fulfill these unmet needs remains to be seen.

Questions answered

• What are the treatment drivers and goals in moderate to severe UC?
• How do current therapies perform on treatment drivers and goals for moderate to severe UC?
• In addition to efficacy, which drug attributes most strongly influence physician prescribing behaviors, and which have a limited impact?
• What are the prevailing areas of unmet need and hidden opportunity in the treatment of moderate to severe UC?
• What trade-offs across clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new UC drug?

Product description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European gastroenterologists fielded in February 2023.

Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Pfizer, Takeda, UCB, BMS.

Key drugs: Humira, Remicade, Entyvio, Xeljanz, Stelara, Zeposia, Rinvoq, adalimumab biosimilars, infliximab biosimilars.